Login / Signup

Intranasal Efudix reduces epistaxis in hereditary hemorrhagic telangiectasia.

Dominique Valérie Clarence de JelF J M DischS KroonJ J MagerF J Verdam
Published in: Angiogenesis (2020)
Unilateral application of 5-FU on a nasal tampon diminished the severity and frequency of epistaxis in all HHT patients. This effect sustained up to three months post-treatment, despite the fact that the contralateral side remained untreated. Subsequently, hemoglobin levels increased. Intranasal 5-FU is a promising entity for further research on epistaxis treatment in HHT patients.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • patient reported
  • replacement therapy